November 29, 2016 - By Adrian Mccoy
Richard Doubleday, the EVP – Chief Commercial Officer of Dexcom Inc made insider trade for 3,182 shares with an average price per share of $70.2 in the company, that are worth $223,350 USD. Currently, Richard Doubleday owns 105,861 shares which make up roughly 0.13% of the Company’s total market cap.
Out of 12 analysts covering Dexcom (NASDAQ:DXCM), 11 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 92% are positive. $120 is the highest target while $70 is the lowest. The $90.88 average target is 27.77% above today’s ($71.13) stock price. Dexcom has been the topic of 18 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating by Benchmark given on Wednesday, February 24. As per Monday, October 31, the company rating was upgraded by BTIG Research. BTIG Research downgraded DexCom, Inc. (NASDAQ:DXCM) on Wednesday, September 14 to “Neutral” rating. Piper Jaffray maintained it with “Buy” rating and $103 target price in Friday, August 7 report. The stock of DexCom, Inc. (NASDAQ:DXCM) has “Buy” rating given on Thursday, October 15 by Sterne Agee CRT. The stock has “Buy” rating given by Jefferies on Wednesday, February 24. JP Morgan maintained DexCom, Inc. (NASDAQ:DXCM) rating on Thursday, September 17. JP Morgan has “Overweight” rating and $120 price target. JP Morgan maintained DexCom, Inc. (NASDAQ:DXCM) rating on Wednesday, February 24. JP Morgan has “Overweight” rating and $100 price target. Leerink Swann upgraded the stock to “Outperform” rating in Thursday, October 15 report. Canaccord Genuity maintained it with “Buy” rating and $70 target price in Wednesday, November 2 report.
Insitutional Activity: The institutional sentiment decreased to 1.1 in 2016 Q2. Its down 0.25, from 1.35 in 2016Q1. The ratio is negative, as 30 funds sold all DexCom, Inc. shares owned while 77 reduced positions. 46 funds bought stakes while 98 increased positions. They now own 82.43 million shares or 5.55% more from 78.09 million shares in 2016Q1.
Manufacturers Life Insurance The holds 0% or 2,289 shares in its portfolio. Ladenburg Thalmann Services has 0.01% invested in the company for 5,529 shares. Tiaa Cref Investment Mgmt Ltd Company holds 0.02% of its portfolio in DexCom, Inc. (NASDAQ:DXCM) for 298,372 shares. Atwood & Palmer last reported 0.02% of its portfolio in the stock. Moreover, Dowling Yahnke has 0.18% invested in DexCom, Inc. (NASDAQ:DXCM) for 18,642 shares. Tocqueville Asset Mngmt Ltd Partnership has invested 0.02% of its portfolio in DexCom, Inc. (NASDAQ:DXCM). Blackrock Fund Advsr holds 1.08M shares or 0.02% of its portfolio. Baillie Gifford accumulated 480,978 shares or 0.07% of the stock. Finemark Natl Bank & owns 435 shares or 0% of their US portfolio. Bamco last reported 0.38% of its portfolio in the stock. Security National holds 0.07% of its portfolio in DexCom, Inc. (NASDAQ:DXCM) for 2,268 shares. Perceptive Advisors Limited Liability Corp holds 0.69% of its portfolio in DexCom, Inc. (NASDAQ:DXCM) for 125,174 shares. King Luther Cap Mgmt has invested 0.02% of its portfolio in DexCom, Inc. (NASDAQ:DXCM). Sectoral Asset Mngmt accumulated 3.23% or 394,466 shares. Zevenbergen Cap Investments Ltd Liability Corporation reported 499,875 shares or 1.86% of all its holdings.
Insider Transactions: Since June 7, 2016, the stock had 0 buys, and 61 sales for $55.78 million net activity. $487,486 worth of DexCom, Inc. (NASDAQ:DXCM) was sold by MOY JEFFREY. LISTER JOHN sold $213,563 worth of stock or 3,417 shares. 7,000 shares were sold by SAYER KEVIN R, worth $635,473. The insider GREGG TERRANCE H sold 10,000 shares worth $927,151. The insider DOUBLEDAY RICHARD sold 3,182 shares worth $258,110. 2,471 shares were sold by ROPER JESS, worth $199,544. Pacelli Steven Robert had sold 10,300 shares worth $934,588.
About 1.01 million shares traded hands. DexCom, Inc. (NASDAQ:DXCM) has risen 5.34% since April 25, 2016 and is uptrending. It has underperformed by 0.68% the S&P500.
Dexcom, Inc. is a medical device company. The company has a market cap of $6.03 billion. The Firm is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. It currently has negative earnings. The Company’s products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile.
According to Zacks Investment Research, “Dexcom Inc. is developing continuous glucose monitoring systems for people with diabetes.”
Analysts await DexCom, Inc. (NASDAQ:DXCM) to report earnings on February, 28. They expect $-0.07 EPS, down 450.00% or $0.09 from last year’s $0.02 per share. After $-0.22 actual EPS reported by DexCom, Inc. for the previous quarter, Wall Street now forecasts -68.18% EPS growth.
More important recent DexCom, Inc. (NASDAQ:DXCM) news were published by: Fool.com which released: “Here’s Why DexCom, Inc. Is Plunging Today” on November 02, 2016, also Prnewswire.com published article titled: “With Health Canada approval, Dexcom G5® Mobile CGM System is the First and ..”, Prnewswire.com published: “Dexcom and Major League Soccer AT&T Rookie of the Year Jordan Morris Kick-off ..” on November 10, 2016. More interesting news about DexCom, Inc. (NASDAQ:DXCM) was released by: Globenewswire.com and their article: “DexCom, Inc. (Nasdaq: DXCM) to Ring The Nasdaq Stock Market Opening Bell” with publication date: November 11, 2016.
Dexcom, Inc. (Dexcom), incorporated on May 13, 1999, is a medical device company. The Firm is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. The Company’s products consist of SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile. The Firm had received Conformite Europeene Marking (CE Mark) approval for its fourth generation continuous glucose monitoring system, the DexCom G4 system, enabling commercialization of the DexCom G4 system in the European Union, Australia, New Zealand and the countries in Asia and Latin America.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Adrian Mccoy